Cargando…

Chimeric virus-like particles presenting tumour-associated MUC1 epitope result in high titers of specific IgG antibodies in the presence of squalene oil-in-water adjuvant: towards safe cancer immunotherapy

BACKGROUND: Immunotherapy is emerging as a powerful treatment approach for several types of cancers. Modulating the immune system to specifically target cancer cells while sparing healthy cells, is a very promising approach for safer therapies and increased survival of cancer patients. Tumour-associ...

Descripción completa

Detalles Bibliográficos
Autores principales: Panasiuk, Mirosława, Zimmer, Karolina, Czarnota, Anna, Narajczyk, Magdalena, Peszyńska-Sularz, Grażyna, Chraniuk, Milena, Hovhannisyan, Lilit, Żołędowska, Sabina, Nidzworski, Dawid, Żaczek, Anna J., Gromadzka, Beata
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8961490/
https://www.ncbi.nlm.nih.gov/pubmed/35351156
http://dx.doi.org/10.1186/s12951-022-01357-1
_version_ 1784677606300319744
author Panasiuk, Mirosława
Zimmer, Karolina
Czarnota, Anna
Narajczyk, Magdalena
Peszyńska-Sularz, Grażyna
Chraniuk, Milena
Hovhannisyan, Lilit
Żołędowska, Sabina
Nidzworski, Dawid
Żaczek, Anna J.
Gromadzka, Beata
author_facet Panasiuk, Mirosława
Zimmer, Karolina
Czarnota, Anna
Narajczyk, Magdalena
Peszyńska-Sularz, Grażyna
Chraniuk, Milena
Hovhannisyan, Lilit
Żołędowska, Sabina
Nidzworski, Dawid
Żaczek, Anna J.
Gromadzka, Beata
author_sort Panasiuk, Mirosława
collection PubMed
description BACKGROUND: Immunotherapy is emerging as a powerful treatment approach for several types of cancers. Modulating the immune system to specifically target cancer cells while sparing healthy cells, is a very promising approach for safer therapies and increased survival of cancer patients. Tumour-associated antigens are favorable targets for cancer immunotherapy, as they are exclusively expressed by the cancer cells, minimizing the risk of an autoimmune reaction. The ability to initiate the activation of the immune system can be achieved by virus-like particles (VLPs) which are safe and potent delivery tools. VLP‐based vaccines have evolved dramatically over the last few decades and showed great potential in preventing infectious diseases. Immunogenic potency of engineered VLPs as a platform for the development of effective therapeutic cancer vaccines has been studied extensively. This study involves recombinant VLPs presenting multiple copies of tumour-specific mucin 1 (MUC1) epitope as a potentially powerful tool for future immunotherapy. RESULTS: In this report VLPs based on the structural protein of Norovirus (NoV VP1) were genetically modified to present multiple copies of tumour-specific MUC1 epitope on their surface. Chimeric MUC1 particles were produced in the eukaryotic Leishmania tarentolae expression system and used in combination with squalene oil-in-water emulsion MF59 adjuvant to immunize BALB/c mice. Sera from vaccinated mice demonstrated high titers of IgG and IgM antibodies which were specifically recognizing MUC1 antigen. CONCLUSIONS: The obtained results show that immunization with recombinant chimeric NoV VP1- MUC1 VLPs result in high titers of MUC1 specific IgG antibodies and show great therapeutic potential as a platform to present tumour-associated antigens. GRAPHICAL ABSTRACT: [Image: see text]
format Online
Article
Text
id pubmed-8961490
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-89614902022-03-29 Chimeric virus-like particles presenting tumour-associated MUC1 epitope result in high titers of specific IgG antibodies in the presence of squalene oil-in-water adjuvant: towards safe cancer immunotherapy Panasiuk, Mirosława Zimmer, Karolina Czarnota, Anna Narajczyk, Magdalena Peszyńska-Sularz, Grażyna Chraniuk, Milena Hovhannisyan, Lilit Żołędowska, Sabina Nidzworski, Dawid Żaczek, Anna J. Gromadzka, Beata J Nanobiotechnology Research BACKGROUND: Immunotherapy is emerging as a powerful treatment approach for several types of cancers. Modulating the immune system to specifically target cancer cells while sparing healthy cells, is a very promising approach for safer therapies and increased survival of cancer patients. Tumour-associated antigens are favorable targets for cancer immunotherapy, as they are exclusively expressed by the cancer cells, minimizing the risk of an autoimmune reaction. The ability to initiate the activation of the immune system can be achieved by virus-like particles (VLPs) which are safe and potent delivery tools. VLP‐based vaccines have evolved dramatically over the last few decades and showed great potential in preventing infectious diseases. Immunogenic potency of engineered VLPs as a platform for the development of effective therapeutic cancer vaccines has been studied extensively. This study involves recombinant VLPs presenting multiple copies of tumour-specific mucin 1 (MUC1) epitope as a potentially powerful tool for future immunotherapy. RESULTS: In this report VLPs based on the structural protein of Norovirus (NoV VP1) were genetically modified to present multiple copies of tumour-specific MUC1 epitope on their surface. Chimeric MUC1 particles were produced in the eukaryotic Leishmania tarentolae expression system and used in combination with squalene oil-in-water emulsion MF59 adjuvant to immunize BALB/c mice. Sera from vaccinated mice demonstrated high titers of IgG and IgM antibodies which were specifically recognizing MUC1 antigen. CONCLUSIONS: The obtained results show that immunization with recombinant chimeric NoV VP1- MUC1 VLPs result in high titers of MUC1 specific IgG antibodies and show great therapeutic potential as a platform to present tumour-associated antigens. GRAPHICAL ABSTRACT: [Image: see text] BioMed Central 2022-03-27 /pmc/articles/PMC8961490/ /pubmed/35351156 http://dx.doi.org/10.1186/s12951-022-01357-1 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Panasiuk, Mirosława
Zimmer, Karolina
Czarnota, Anna
Narajczyk, Magdalena
Peszyńska-Sularz, Grażyna
Chraniuk, Milena
Hovhannisyan, Lilit
Żołędowska, Sabina
Nidzworski, Dawid
Żaczek, Anna J.
Gromadzka, Beata
Chimeric virus-like particles presenting tumour-associated MUC1 epitope result in high titers of specific IgG antibodies in the presence of squalene oil-in-water adjuvant: towards safe cancer immunotherapy
title Chimeric virus-like particles presenting tumour-associated MUC1 epitope result in high titers of specific IgG antibodies in the presence of squalene oil-in-water adjuvant: towards safe cancer immunotherapy
title_full Chimeric virus-like particles presenting tumour-associated MUC1 epitope result in high titers of specific IgG antibodies in the presence of squalene oil-in-water adjuvant: towards safe cancer immunotherapy
title_fullStr Chimeric virus-like particles presenting tumour-associated MUC1 epitope result in high titers of specific IgG antibodies in the presence of squalene oil-in-water adjuvant: towards safe cancer immunotherapy
title_full_unstemmed Chimeric virus-like particles presenting tumour-associated MUC1 epitope result in high titers of specific IgG antibodies in the presence of squalene oil-in-water adjuvant: towards safe cancer immunotherapy
title_short Chimeric virus-like particles presenting tumour-associated MUC1 epitope result in high titers of specific IgG antibodies in the presence of squalene oil-in-water adjuvant: towards safe cancer immunotherapy
title_sort chimeric virus-like particles presenting tumour-associated muc1 epitope result in high titers of specific igg antibodies in the presence of squalene oil-in-water adjuvant: towards safe cancer immunotherapy
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8961490/
https://www.ncbi.nlm.nih.gov/pubmed/35351156
http://dx.doi.org/10.1186/s12951-022-01357-1
work_keys_str_mv AT panasiukmirosława chimericviruslikeparticlespresentingtumourassociatedmuc1epitoperesultinhightitersofspecificiggantibodiesinthepresenceofsqualeneoilinwateradjuvanttowardssafecancerimmunotherapy
AT zimmerkarolina chimericviruslikeparticlespresentingtumourassociatedmuc1epitoperesultinhightitersofspecificiggantibodiesinthepresenceofsqualeneoilinwateradjuvanttowardssafecancerimmunotherapy
AT czarnotaanna chimericviruslikeparticlespresentingtumourassociatedmuc1epitoperesultinhightitersofspecificiggantibodiesinthepresenceofsqualeneoilinwateradjuvanttowardssafecancerimmunotherapy
AT narajczykmagdalena chimericviruslikeparticlespresentingtumourassociatedmuc1epitoperesultinhightitersofspecificiggantibodiesinthepresenceofsqualeneoilinwateradjuvanttowardssafecancerimmunotherapy
AT peszynskasularzgrazyna chimericviruslikeparticlespresentingtumourassociatedmuc1epitoperesultinhightitersofspecificiggantibodiesinthepresenceofsqualeneoilinwateradjuvanttowardssafecancerimmunotherapy
AT chraniukmilena chimericviruslikeparticlespresentingtumourassociatedmuc1epitoperesultinhightitersofspecificiggantibodiesinthepresenceofsqualeneoilinwateradjuvanttowardssafecancerimmunotherapy
AT hovhannisyanlilit chimericviruslikeparticlespresentingtumourassociatedmuc1epitoperesultinhightitersofspecificiggantibodiesinthepresenceofsqualeneoilinwateradjuvanttowardssafecancerimmunotherapy
AT zołedowskasabina chimericviruslikeparticlespresentingtumourassociatedmuc1epitoperesultinhightitersofspecificiggantibodiesinthepresenceofsqualeneoilinwateradjuvanttowardssafecancerimmunotherapy
AT nidzworskidawid chimericviruslikeparticlespresentingtumourassociatedmuc1epitoperesultinhightitersofspecificiggantibodiesinthepresenceofsqualeneoilinwateradjuvanttowardssafecancerimmunotherapy
AT zaczekannaj chimericviruslikeparticlespresentingtumourassociatedmuc1epitoperesultinhightitersofspecificiggantibodiesinthepresenceofsqualeneoilinwateradjuvanttowardssafecancerimmunotherapy
AT gromadzkabeata chimericviruslikeparticlespresentingtumourassociatedmuc1epitoperesultinhightitersofspecificiggantibodiesinthepresenceofsqualeneoilinwateradjuvanttowardssafecancerimmunotherapy